Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Loss of tumor suppressor Merlin in advanced breast cancer is due to post-translational regulation.

Morrow KA, Das S, Metge BJ, Ye K, Mulekar MS, Tucker JA, Samant RS, Shevde LA.

J Biol Chem. 2011 Nov 18;286(46):40376-85. doi: 10.1074/jbc.M111.250035. Epub 2011 Sep 30.

2.

Loss of tumor suppressor Merlin results in aberrant activation of Wnt/β-catenin signaling in cancer.

Morrow KA, Das S, Meng E, Menezes ME, Bailey SK, Metge BJ, Buchsbaum DJ, Samant RS, Shevde LA.

Oncotarget. 2016 Apr 5;7(14):17991-8005. doi: 10.18632/oncotarget.7494.

3.

AMOTL1 Promotes Breast Cancer Progression and Is Antagonized by Merlin.

Couderc C, Boin A, Fuhrmann L, Vincent-Salomon A, Mandati V, Kieffer Y, Mechta-Grigoriou F, Del Maestro L, Chavrier P, Vallerand D, Brito I, Dubois T, De Koning L, Bouvard D, Louvard D, Gautreau A, Lallemand D.

Neoplasia. 2016 Jan;18(1):10-24. doi: 10.1016/j.neo.2015.11.010.

4.

Akt phosphorylation regulates the tumour-suppressor merlin through ubiquitination and degradation.

Tang X, Jang SW, Wang X, Liu Z, Bahr SM, Sun SY, Brat D, Gutmann DH, Ye K.

Nat Cell Biol. 2007 Oct;9(10):1199-207. Epub 2007 Sep 23.

PMID:
17891137
5.

Hypoxia-driven osteopontin contributes to breast tumor growth through modulation of HIF1α-mediated VEGF-dependent angiogenesis.

Raja R, Kale S, Thorat D, Soundararajan G, Lohite K, Mane A, Karnik S, Kundu GC.

Oncogene. 2014 Apr 17;33(16):2053-64. doi: 10.1038/onc.2013.171. Epub 2013 Jun 3.

PMID:
23728336
6.

Osteopontin knockdown inhibits αv,β3 integrin-induced cell migration and invasion and promotes apoptosis of breast cancer cells by inducing autophagy and inactivating the PI3K/Akt/mTOR pathway.

Zhang H, Guo M, Chen JH, Wang Z, Du XF, Liu PX, Li WH.

Cell Physiol Biochem. 2014;33(4):991-1002. doi: 10.1159/000358670. Epub 2014 Apr 1.

7.

Deletion of the thrombin cleavage domain of osteopontin mediates breast cancer cell adhesion, proteolytic activity, tumorgenicity, and metastasis.

Beausoleil MS, Schulze EB, Goodale D, Postenka CO, Allan AL.

BMC Cancer. 2011 Jan 19;11:25. doi: 10.1186/1471-2407-11-25.

8.

Multistep phosphorylation by oncogenic kinases enhances the degradation of the NF2 tumor suppressor merlin.

Laulajainen M, Muranen T, Nyman TA, Carpén O, Grönholm M.

Neoplasia. 2011 Jul;13(7):643-52.

9.

Merlin sumoylation is required for its tumor suppressor activity.

Qi Q, Liu X, Brat DJ, Ye K.

Oncogene. 2014 Oct 9;33(41):4893-903. doi: 10.1038/onc.2013.438. Epub 2013 Oct 28.

PMID:
24166499
10.

Beta(3) integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin.

Furger KA, Allan AL, Wilson SM, Hota C, Vantyghem SA, Postenka CO, Al-Katib W, Chambers AF, Tuck AB.

Mol Cancer Res. 2003 Sep;1(11):810-9.

11.

Merlin is a negative regulator of human melanoma growth.

Murray LB, Lau YK, Yu Q.

PLoS One. 2012;7(8):e43295. doi: 10.1371/journal.pone.0043295. Epub 2012 Aug 17.

12.

Oncogenic role of Merlin/NF2 in glioblastoma.

Guerrero PA, Yin W, Camacho L, Marchetti D.

Oncogene. 2015 May 14;34(20):2621-30. doi: 10.1038/onc.2014.185. Epub 2014 Jul 21.

13.

Phosphorylation of merlin regulates its stability and tumor suppressive activity.

Ye K.

Cell Adh Migr. 2007 Oct-Dec;1(4):196-8. Epub 2007 Oct 22. Review.

14.

Down-regulation of osteopontin attenuates breast tumour progression in vivo.

Chakraborty G, Jain S, Patil TV, Kundu GC.

J Cell Mol Med. 2008 Dec;12(6A):2305-18. doi: 10.1111/j.1582-4934.2008.00263.x. Epub 2008 Feb 4.

15.

Loss of NF2/Merlin expression in advanced sporadic colorectal cancer.

Cačev T, Aralica G, Lončar B, Kapitanović S.

Cell Oncol (Dordr). 2014 Feb;37(1):69-77. doi: 10.1007/s13402-013-0164-2. Epub 2013 Dec 10.

PMID:
24323642
16.

Large isoform of MRJ (DNAJB6) reduces malignant activity of breast cancer.

Mitra A, Fillmore RA, Metge BJ, Rajesh M, Xi Y, King J, Ju J, Pannell L, Shevde LA, Samant RS.

Breast Cancer Res. 2008;10(2):R22. doi: 10.1186/bcr1874. Epub 2008 Mar 7.

17.

Andrographolide inhibits osteopontin expression and breast tumor growth through down regulation of PI3 kinase/Akt signaling pathway.

Kumar S, Patil HS, Sharma P, Kumar D, Dasari S, Puranik VG, Thulasiram HV, Kundu GC.

Curr Mol Med. 2012 Sep;12(8):952-66.

PMID:
22804248
18.

Merlin is a potent inhibitor of glioma growth.

Lau YK, Murray LB, Houshmandi SS, Xu Y, Gutmann DH, Yu Q.

Cancer Res. 2008 Jul 15;68(14):5733-42. doi: 10.1158/0008-5472.CAN-08-0190.

19.

Differential gene expression of TGF-beta family members and osteopontin in breast tumor tissue: analysis by real-time quantitative PCR.

Reinholz MM, Iturria SJ, Ingle JN, Roche PC.

Breast Cancer Res Treat. 2002 Jun;74(3):255-69.

PMID:
12206515
20.

Merlin: the wizard requires protein stability to function as a tumor suppressor.

Morrow KA, Shevde LA.

Biochim Biophys Acta. 2012 Dec;1826(2):400-6. doi: 10.1016/j.bbcan.2012.06.005. Epub 2012 Jun 30. Review.

Supplemental Content

Support Center